ScripLess than two months after saying that it would wind down its business of stem cell-based therapies for blood cancers, Vor Bio of the US has bounced back, rebranding as an autoimmune disease company a
ScripPureTech’s idiopathic pulmonary fibrosis (IPF) candidate, deupirfenidone, is ready to enter a pivotal study after showing improved efficacy compared with standard treatment in a Phase II study. The pr
ScripIt looks as though nothing will come of the takeover talks PureTech Health has held with Nordic Capital Epsilon but there is a compelling argument for taking its ‘hub-and-spoke’ business private in th
ScripThe busy week for the idiopathic pulmonary fibrosis (IPF) space has continued apace with the news that Roche is selling off rights to one of the two drugs currently approved for the debilitating and f